Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
$0.39
$0.39
$0.23
$2.83
$26.62M1.55943,490 shsN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$9.04
+1.7%
$7.78
$3.96
$9.11
$245.37M0.3992,734 shs123,640 shs
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
$0.17
$0.03
$2.51
$5.04M0.939.20 million shs23.04 million shs
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
$7.27
-2.9%
$2.06
$0.26
$3.77
$191.06M2.06168,718 shs91,424 shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$3.55
+2.3%
$3.20
$2.65
$9.55
$192.02M0.85485,134 shs902,881 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.00%0.00%0.00%0.00%0.00%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
+1.69%+4.09%+8.78%+80.44%+50.67%
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
0.00%0.00%0.00%0.00%0.00%
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
+1.77%+3.31%+3.74%+11.46%+30.94%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
+2.31%+8.23%+2.60%+11.99%-56.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.1839 of 5 stars
0.00.00.03.80.60.00.0
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
2.3274 of 5 stars
3.61.00.00.01.83.30.0
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
N/AN/AN/AN/AN/AN/AN/AN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
1.497 of 5 stars
0.04.00.04.70.60.80.6
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.8267 of 5 stars
3.61.00.04.61.90.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.00
N/AN/AN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
3.25
Buy$13.0043.81% Upside
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
0.00
N/AN/AN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
0.00
N/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.13
Buy$13.39277.18% Upside

Current Analyst Ratings Breakdown

Latest AGTC, FENC, VYGR, GMDA, and LOGC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
5/14/2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $13.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
$320K83.19N/AN/A$0.26 per share1.51
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$47.54M5.25$0.03 per share275.27($0.21) per share-43.05
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
$1.78M0.00N/AN/A($0.02) per share0.00
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
$287M0.67N/AN/A$8.96 per share0.81
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$80M2.46N/AN/A$5.49 per share0.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-$440K-$0.51N/AN/AN/A-45.52%N/A-26.37%8/12/2025 (Estimated)
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
-$317M-$5.79N/AN/A-141.03%-81.98%-52.13%N/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)

Latest AGTC, FENC, VYGR, GMDA, and LOGC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.48N/AN/AN/A$9.50 millionN/A
5/13/2025Q1 2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 million
5/9/2025Q1 2025
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
N/A-$0.27N/A-$0.27N/AN/A
5/6/2025Q1 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
N/AN/AN/AN/AN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/AN/AN/AN/AN/A
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
N/AN/AN/AN/AN/A
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
N/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
0.39
1.40
1.40
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/A
5.13
4.97
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
213.14
2.16
2.09
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
N/A
31.60
31.60
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
6.10
6.10
CompanyEmployeesShares OutstandingFree FloatOptionable
Applied Genetic Technologies Co. stock logo
AGTC
Applied Genetic Technologies
8367.63 million64.86 millionOptionable
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
1027.60 million24.35 millionOptionable
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
143154.05 million143.70 millionOptionable
LogicBio Therapeutics, Inc. stock logo
LOGC
LogicBio Therapeutics
6226.28 million24.16 millionOptionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
10055.34 million51.80 millionOptionable

Recent News About These Companies

VYGR Voyager Therapeutics, Inc. - Seeking Alpha
Voyager Technologies Soars with IPO Success
Voyager Technologies Shares Soar In Market Debut
Voyager raises $383 million from upsized IPO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Applied Genetic Technologies stock logo

Applied Genetic Technologies NASDAQ:AGTC

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Adherex Technologies stock logo

Adherex Technologies NASDAQ:FENC

$9.04 +0.15 (+1.69%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$9.05 +0.01 (+0.11%)
As of 07/10/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Gamida Cell stock logo

Gamida Cell NASDAQ:GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

LogicBio Therapeutics stock logo

LogicBio Therapeutics NASDAQ:LOGC

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$3.55 +0.08 (+2.31%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$3.65 +0.10 (+2.82%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.